176 related articles for article (PubMed ID: 12239335)
1. Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.
Quiñones-Mateu ME; Tadele M; Parera M; Mas A; Weber J; Rangel HR; Chakraborty B; Clotet B; Domingo E; Menéndez-Arias L; Martínez MA
J Virol; 2002 Oct; 76(20):10546-52. PubMed ID: 12239335
[TBL] [Abstract][Full Text] [Related]
2. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
[TBL] [Abstract][Full Text] [Related]
3. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
[TBL] [Abstract][Full Text] [Related]
4. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
Maldonado JO; Mansky LM
Viruses; 2018 Jul; 10(7):. PubMed ID: 30029500
[TBL] [Abstract][Full Text] [Related]
5. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
6. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
7. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
8. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
9. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
10. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
11. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
[TBL] [Abstract][Full Text] [Related]
12. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Andreatta KN; Miller MD; White KL
Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
15. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
16. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
Bulgheroni E; Croce F; Citterio P; Viganò O; Visonà R; Sala E; Galli M; Rusconi S
J Clin Virol; 2004 Jan; 29(1):27-32. PubMed ID: 14675866
[TBL] [Abstract][Full Text] [Related]
17. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Ntemgwa M; Wainberg MA; Oliveira M; Moisi D; Lalonde R; Micheli V; Brenner BG
Antimicrob Agents Chemother; 2007 Nov; 51(11):3861-9. PubMed ID: 17724152
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
19. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Li Z; Terry B; Olds W; Protack T; Deminie C; Minassian B; Nowicka-Sans B; Sun Y; Dicker I; Hwang C; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Nov; 57(11):5500-8. PubMed ID: 23979732
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
